The Use of Human Liver Cell Model and Cytochrome P450 Substrate—Inhibitor Panel for Studies of Dasatinib and Warfarin Interactions


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The possibility of interactions between warfarin and dasatinib and their interactions with other drugs metabolized by cytochrome P450 isoform CYP3A4 was demonstrated using a previously created cytochrome P450 substrate—inhibitor panel for preclinical in vitro studies of drug biotransformation on a 3D histotypical microfluidic cell model of human liver (liver-on-a-chip technology). Dasatinib and warfarin are inhibitors of CYP2C19 isoform and hence, can interfere the drugs metabolized by this isoform. Our findings are in line with the data obtained on primary culture of human hepatocytes and suggest that the model can be used in preclinical in vitro studies of drugs.

作者简介

A. Zakharyants

BioClinicum Center

Email: o.burmistrova@bioclinicum.com
俄罗斯联邦, Moscow

O. Burmistrova

BioClinicum Center

编辑信件的主要联系方式.
Email: o.burmistrova@bioclinicum.com
俄罗斯联邦, Moscow

A. Poloznikov

BioClinicum Center

Email: o.burmistrova@bioclinicum.com
俄罗斯联邦, Moscow


版权所有 © Springer Science+Business Media New York, 2017
##common.cookie##